Lupin Pharmaceuticals Inc. the wholly owned USA subsidiary of Lupin Ltd. has successfully acquired the US FDA approval of SUPRAX (Cefixime) 400 mg capsules that is used for the treatment of bacterial infections. With attainment of the approval, Lupin is in plans of initiating commercialization and shipment of the capsule at the earliest. The capsule is currently available in 100 mg/5ml and 200 mg/5ml suspensions as well as 400 mg tablets.
The US FDA approval will strengthen Lupin’s SUPRAX franchise and address the needs of patients for treatment of the indicated infections.
Source: Gnom
